Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine + Pembrolizumab in AML
NCT02845297Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2016
- Primary completion
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in acute myeloid leukemia (AML) (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Maximal Tolerable Dose of Pembrolizumab. Started Jul 2016; status: completed.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02845297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02845297.